Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...

罗氏这次重组之前已经对Spark进行了调整，2024年因重组该部门产生了1.84亿美元 （约合1.62亿瑞士法郎） 的重组成本。对于新的“根本性重组”，罗氏初步估计2025年将额外产生3.4亿美元 （约合3亿瑞士法郎） 的成本。

近日，罗氏对旗下基因疗法子公司Spark Therapeutics启动“根本性重组”。 这家2019年以43亿美元高价收购的明星企业，如今被彻底纳入罗氏制药部门，并因商誉减值损失24亿美元。

Luxturna is a single injection of a genetically engineered virus expressing the retinal pigment protein (RPE65) that is deficient in people with the condition. If approved, it will put Spark ...

But now the FDA has rubber-stamped the approval of Luxturna, the first ever gene therapy it has backed, all the attention is now on Spark, and what price it plans to charge for the therapy.

In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...

Philadelphia’s Spark Therapeutics is going through a “fundamental reorganization” by its owner, Swiss pharmaceutical giant Roche, which has written off the regional biotech leader as a financial loss ...

In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...

Spark has the distinction of being the first company to receive FDA approval of a gene therapy treatment for an inherited disease. The product, Luxturna, was approved in late 2017 as a one-time ...